Showing 5591-5600 of 9117 results for "".
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedurehttps://practicaldermatology.com/news/biotin-supplements-caused-misleading-test-results-almost-led-to-an-unnecessary-procedure/2457758/A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, whic
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017https://practicaldermatology.com/news/asds-skin-cancer-treatment-ranks-as-most-performed-procedure-of-2017/2457761/The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 – over 10 percent more than 2016 and doubling since 2012. For the sixth year in a row, the 2017 ASDS Survey on Dermatologic Procedures reveale
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- And the Winner Is...Consumer Reports Releases Annual Sunscreen Ratingshttps://practicaldermatology.com/news/consumer-reports-releases-annual-sunscreen-ratings/2457769/Drumroll please… The annual Consumer Reports sunscreen ratings are in. Just one product, La Roche-Posay Anthelios 60 Melt-In Sunscreen Milk, came
- Teledermoscopy Speeds Time to Case Resolution. In Australiahttps://practicaldermatology.com/news/teledermoscopy-speeds-time-to-case-resolution-in-australia/2457768/Teledermatology for skin cancer referral and triage would add to the costs of care but would result in more rapid clinical resolution&m
- Skin Cancer Foundation Hits the Roadhttps://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road/2457771/The Skin Cancer Foundation kicks off the second year of its mobile education and screeing program called Destination: Healthy Skin. Starting Tuesday, May 15, in New York City, the tour will stop in 15 cities ov
- Valeant is Becoming Bausch Health Companies, Inc.https://practicaldermatology.com/news/valeant-is-becoming-bausch-health-companies-inc/2457770/Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on th
- Industry Vet James P. Hartman Named New Chief Commercial Officer at Alastinhttps://practicaldermatology.com/news/industry-vet-james-p-hartman-named-new-chief-commercial-officer-at-alastin/2457772/James P. Hartman is the new Chief Commercial Officer of Alastin Skincare, Inc.— effective May 14, 2018. Mr. Hartman recently served as Vice President & General Manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Sol